(19)
(11) EP 3 636 781 A8

(12) CORRECTED EUROPEAN PATENT APPLICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 A1)

(48) Corrigendum issued on:
17.06.2020 Bulletin 2020/25

(43) Date of publication:
15.04.2020 Bulletin 2020/16

(21) Application number: 18199748.7

(22) Date of filing: 10.10.2018
(51) International Patent Classification (IPC): 
C12Q 1/70(2006.01)
 A61K 31/00(2006.01)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(71) Applicant: Heinrich-Pette-Institut Leibniz-Institut für Experimentelle Virologie
20251 Hamburg (DE)

(72) Inventors:
  • Altfeld, Marcus
    20251 Hamburg (DE)
  • Martrus Zapater, Glòria
    20251 Hamburg (DE)

(74) Representative: Uexküll & Stolberg 
Partnerschaft von Patent- und Rechtsanwälten mbB Beselerstraße 4
22607 Hamburg
22607 Hamburg (DE)

   


(54) NOVEL SCREENING ASSAYS FOR IDENTIFYING COMPOUNDS REVERSING HIV-1 LATENCY


(57) The present invention relates to a method for identifying compounds which reverse HIV-1 latency in a subject and can therefore be therapeutically used for eliminating a latent viral reservoir in a subject infected with HIV-1. Further, the present invention relates to a method for identifying compounds which stabilize HIV-1 latency in a subject and can therefore be therapeutically used for preventing replication and outgrowth of latent HIV-1. In yet another aspect, the present invention relates to a compound that increases or decreases the expression level of the HIV-1 Vpu gene for use in method of treating an HIV-1 infection in a subject in need thereof. In yet another aspect, the present invention relates to a compound that increases or decreases the binding between the HIV-1 Vpu protein and NF-κB for use in method of treating an HIV-1 infection in a subject in need thereof.